Cancer & Oncology Clinical Trials Update: Week 25, 2026

Published June 19, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

This phase III trial is testing whether adding tucatinib to T-DM1 can better prevent breast cancer from coming back in people with high-risk HER2-positive breast cancer. With more than 1000 participants enrolled across the US, Canada, and Puerto Rico, the study may offer a new treatment option that improves long-term outcomes by reducing relapse rates after initial therapy.

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

This phase III study looks at a new combination of immunotherapy drugs for patients with advanced non-small cell lung cancer that has high PD-L1 levels. The trial could provide a new treatment option that helps patients live longer or better compared to current therapies. It is active with patients enrolled globally but is not currently recruiting.

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

This large phase III trial evaluated whether adding canakinumab to pembrolizumab and chemotherapy improves survival or safety for people with advanced non-small cell lung cancer. With over 600 patients enrolled worldwide, the results contribute important knowledge about new ways to improve treatment for this common lung cancer type.

Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer

This phase III trial is comparing a new drug called YL202 to standard chemotherapy in patients with advanced non-small cell lung cancer that has specific EGFR mutations. Recruiting in China, the study aims to see if YL202 can help patients who have not responded to other treatments, potentially offering a new option with different side effects.

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

This phase III trial tests whether changing the timing of doses of Lutetium 177Lu PSMA RLT can improve quality of life for men with advanced prostate cancer that no longer responds to hormone therapy. The study seeks to delay treatment side effects without shortening lifespan and is currently recruiting patients in the United States.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.